Cancer Stem Cell News Volume 3.23 | Jun 18 2014

Establishment of Highly Tumorigenic Human Colorectal Cancer Cell Line (CR4) with Properties of Putative Cancer Stem Cells
Researchers report the establishment of a novel cancer-initiating cell-enriched, highly tumorigenic and clonogenic colon cancer cell line, CR4, derived from liver metastasis. [PLoS One] Full Article

Knockdown of miR-210 Decreases Hypoxic Glioma Stem Cells Stemness and Radioresistance
To explore the possibility of miR-210 as an effective therapeutic target to hypoxic glioma stem cells, scientists employed lentiviral-mediated anti-sense miR-210 gene transfer technique to knockdown miR-210 expression and analyze phenotypic changes in hypoxic U87s and SHG44s cells. [Exp Cell Res] Abstract

Cancer Stem Cell Phenotype Is Supported by Secretory Phospholipase A₂ in Human Lung Cancer Cells
Viral knockdown and chemical inhibition of secretory phospholipase A₂ group IIa (sPLA₂) reduce tumorsphere formation in lung cancer cells demonstrate for the first time that sPLA₂ plays an important role in cancer stem cells. [Ann Thorac Surg] Abstract

QKI Impairs Self-Renewal and Tumorigenicity of Oral Cancer Cells via Repression of SOX2
Researchers showed that reduced Quaking (QKI) levels were observed in many human oral cancer samples. Moreover further reduction of QKI expression in cancer stem cells (CSCs) was detected compared with non-CSCs in oral cancer cell lines. [Cancer Biol Ther] Full Article

Characterization of Side Population Cells Isolated from the Colon Cancer Cell Line SW480
The self-renewal, differentiated progeny, clone formation, proliferation, invasion ability, cell cycle, chemosensitivity and tumorigenic properties in side population (SP) and non-SP cells were investigated through in vitro culture and in vivo serial transplantation. [Int J Oncol] Abstract

Resistance of Oral Squamous Cell Carcinoma Cells to Cetuximab Is Associated with EGFR Insensitivity and Enhanced Stem Cell-Like Potency
Researchers characterized cetuximab-resistant oral squamous cell carcinoma (OSCC) cell lines. The human OSCC cell lines HSC3, HSC4 and SAS were used. Cetuximab-resistant SAS cells not only engaged in epidermal growth factor receptor (EGFR)-independent growth but also exhibited stem cell-like properties. [Oncol Rep] Abstract

Cancer Stem Cell Differentiation: TGFβ1 and Versican May Trigger Molecules for the Organization of Tumor Spheroids
Scientists constructed an in vitro differentiation model for cancer stem cells (CSCs). CSCs isolated and proliferated for one passage were maintained as monolayers or spheroid-forming cells with serum included media for differentiation process. [Oncol Rep] Abstract

Heading to ISSCR 2014 in Vancouver?
Come Visit Connexon Creative at Booth #507 and Enter to Win $100 Amazon Gift Card!

Epigenetic Mechanisms of Tumorigenicity Manifesting in Stem Cells
The cancer-related epigenetic mechanisms found in pluripotent stem cells and cancer cells are discussed, focusing on both the similarities and the differences. [Oncogene] Abstract

Targeting the NF-E2-Related Factor 2 Pathway: A Novel Strategy for Glioblastoma
The authors discuss a novel framework of nuclear factor erythroid 2-related factor 2 (Nrf2) in the regulation of glioblastoma and the mechanisms regarding the downregulation of Nrf2 in treating glioblastoma. [Oncol Rep] Abstract

Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.

ImmunoGen, Inc. Announces Preclinical Findings for IMGN779, a Potential Treatment for Acute Myeloid Leukemia
ImmunoGen, Inc. disclosed for the first time preclinical data for IMGN779. IMGN779 is a novel, CD33-targeting, DNA-alkylating antibody-drug conjugate that is a potential treatment for acute myeloid leukemia. [Press release from ImmunoGen, Inc. discussing research presented at the 19^th Congress of the European Hematology Association (EHA), Milan] Press Release

Boston Biomedical Announces Clinical Data Presentation of Its Cancer Stem Cell Inhibitor Programs
Clinical data were presented for BBI608 and BBI503, novel agents targeting cancer stem cells that have been developed by Boston Biomedical. [Press release from Boston Biomedical discussing research presented at the 2014 American Society of Clinical Oncology (ASCO) 50^th Annual Meeting, Chicago] Press Release

From our sponsor: Free mouse hematopoietic progenitors wallchart. Request your copy.

Western Oncolytics Receives $275,000 Seed Funding for Development of Cancer Immunotherapy
Western Oncolytics Ltd. has closed $275,000 in seed funding. The proceeds are planned to set a path toward clinical trials and execute initial manufacturing for its novel virus-based cancer therapy, which delivers genes to guide the immune system to kill cancer cells. [PR Newswire Association LLC] Press Release

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the cancer stem cell community.

NEW Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

NEW Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Postdoctoral Fellow – Stem Cells and Cancer (Albert Einstein College of Medicine in New York)

Postdoctoral Fellow – Cancer and Stem Cell Biology (University of Pennsylvania)

Research Officers – Cancer Stem Cell Biology (Genome Institute of Singapore)

PhD Scholarship – Inorganic Nanoparticles for Cancer Stem Cell Targeting and Detection (The Italian Institute of Technology)

Positions for Principal Investigators – Translational Medical Research of Cancer Biology (Shanghai Institute of Biochemistry and Cell Biology)

Postdoctoral Position – Stem Cell Biology/Cancer Biology (Oregon Health and Science University)

Postdoctoral Researcher – Cancer Genomics (University of Chicago)

Postdoctoral Fellowships – Cancer Research (German Cancer Research Center [DKFZ])

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.